{
    "General": {
        "Code": "3KY",
        "Type": "Common Stock",
        "Name": "HANSOH PHARMAC. HD-00001",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "KYG549581067",
        "LEI": null,
        "PrimaryTicker": null,
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "December",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Drug Manufacturers-Specialty & Generic",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Pharmaceuticals",
        "GicSubIndustry": "Pharmaceuticals",
        "Description": "Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infectives, central nervous system diseases, metabolic diseases, and other therapeutic areas. Its principal products include Mailingda, Ameile, Hansoh Xinfu, Fulaimei, Hengmu, Xinwei, Tanneng, Ameining, Oulanning, Ailanning, Zetan, Ruibote, Fulaidi, Puruian, Fulairui, Pulaile, Zefei, Xinmei, Xintai, and Gainuo drugs, as well as XINYUE and Hengsen. The company serves pharmaceutical product distributors. It has a collaborations with NiKang Therapeutics to develop and commercialize NKT2152; TiumBio to develop and commercialize TU2670 for the treatment of endometriosis, uterine fibroids and other indications; Global Health Drug Discovery Institute to develop, manufacture, and commercialize the GDI-4405 series of anti-novel coronavirus; KiOmed Pharma SA to develop and commercialize KiOmedinevsOne for the treatment of osteoarthritis; and Biotheus Inc. to develop and commercialize PM1080. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 10523,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 7059786240,
        "MarketCapitalizationMln": 7059.7862,
        "EBITDA": 2931855104,
        "PERatio": 19.6667,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 3.826,
        "DividendShare": 0.088,
        "DividendYield": 0.0192,
        "EarningsShare": 0.06,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2022-12-31",
        "ProfitMargin": 0.2754,
        "OperatingMarginTTM": 0.2779,
        "ReturnOnAssetsTTM": 0.057,
        "ReturnOnEquityTTM": 0.1211,
        "RevenueTTM": 9382410240,
        "RevenuePerShareTTM": 1.586,
        "QuarterlyRevenueGrowthYOY": -0.106,
        "GrossProfitTTM": 8512220000,
        "DilutedEpsTTM": 0.06,
        "QuarterlyEarningsGrowthYOY": -0.087
    },
    "Valuation": {
        "TrailingPE": 19.6667,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": -9911992320,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 5933349888,
        "SharesFloat": 1074471362,
        "PercentInsiders": 81.76400000000001,
        "PercentInstitutions": 8.19,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 0.619,
        "52WeekHigh": 2.0917,
        "52WeekLow": 1.11,
        "50DayMA": 1.3634,
        "200DayMA": 1.6023,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0.02,
        "ForwardAnnualDividendYield": 0.0192,
        "PayoutRatio": 0.2779,
        "DividendDate": null,
        "ExDividendDate": "2023-06-05",
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {
            "0": {
                "Year": 2021,
                "Count": 1
            },
            "1": {
                "Year": 2022,
                "Count": 3
            },
            "2": {
                "Year": 2023,
                "Count": 1
            }
        }
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}